Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

6 of 3 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2
6(100.0%)
6Total
Phase 2(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03691714Phase 2Completed

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Role: lead

NCT04414540Phase 2Active Not Recruiting

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

Role: lead

NCT05074940Phase 2Active Not Recruiting

Amivantamab in Adenoid Cystic Carcinoma

Role: lead

NCT04313504Phase 2Completed

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Role: lead

NCT03355560Phase 2Completed

Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

Role: lead

NCT02641093Phase 2Active Not Recruiting

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Role: lead

All 6 trials loaded